Post by Lionel Couzi

🩺🔬  “Refractory CMV: Real-World Evidence Serving a New Therapeutic Option” The Department of Nephrology, Transplantation, Dialysis and Apheresis at CHU de Bordeaux has published in the American Journal of Transplantation the first French nationwide real-world study evaluating maribavir in refractory CMV infections in kidney transplant recipients. 👉 Nationwide multicenter study (22 centers) 👉 88 kidney transplant recipients included 👉 First identification of predictive factors for virological response These results help better stratify high-risk patients and optimize therapeutic strategies for the most complex cases of CMV infection after kidney transplantation. This publication highlights the strength of the French collaborative kidney transplantation network, capable of generating robust real-world evidence directly impacting patient care. 👏 Sincere thanks to all participating centers and teams: CHU de Bordeaux CHU de Limoges CHU de Strasbourg CHU de Toulouse CHU de Dijon CHU de La Réunion Hôpital Necker-Enfants Malades CHU d’Angers CHU de Clermont-Ferrand CHU de Tours Hôpital Henri-Mondor CHU de Nancy CHU de Nice CHU de Saint-Étienne Hôpital Pitié-Salpêtrière CHU de Lille CHU de Nantes AP-HM CHU Amiens-Picardie Hospices Civils de Lyon CHU de Rouen CHU de Grenoble #Transplantation #CMV #ClinicalResearch #RealWorldEvidence #KidneyTransplant #InnovationInHealth #FrenchResearch